Compound Research Library

Synthetic pentadecapeptide (GEPPPGKPADDAGLV) derived from Body Protection Compound. Studied for tissue repair signalling, angiogenic modulation via VEGFR-2, and gastrointestinal mucosal integrity.

Pre-mixed combination of BPC-157 and TB-500 in a co-lyophilised blend. Studied in preclinical models for multi-pathway tissue repair signalling, angiogenic modulation, and cytoskeletal remodelling via complementary mechanisms.

Glycine-Histidine-Lysine copper(II) complex. Studied for collagen/elastin biosynthesis, VEGF-driven angiogenesis, NF-κB anti-inflammatory signalling, and skin matrix remodelling research.

γ-Glu-Cys-Gly tripeptide and primary intracellular antioxidant. Studied for GPx catalysis, GSH/GSSG redox cycle, Phase II detoxification, and Nrf2/ARE pathway regulation.

ACTH(4-7) heptapeptide extended with a Pro-Gly-Pro stabilising tail. Studied in CNS research for BDNF and NGF upregulation, dopaminergic modulation and neuroprotective signalling.

Tuftsin-derived heptapeptide. Studied for indirect GABAergic modulation, BDNF regulation, serotonergic metabolism and immunomodulatory signalling derived from its tuftsin parent sequence.

Delta sleep-inducing peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). Studied for GABAergic sleep regulation, delta EEG power modulation, and HPA axis suppression in preclinical models.

Cyclic nonapeptide (CYIQNCPLG-NH2) acting via OXTR/Gq. Studied in social cognition, amygdala threat-salience, HPA axis modulation, and neuroendocrine social reward research models.

C-terminal decapeptide of KP-54. Studied as a GPR54/Kiss1R agonist for GnRH pulsatile secretion, HPG axis activation, and reproductive neuroendocrinology following the landmark NEJM 2003 discoveries.

Selective MC3R/MC4R agonist. Studied in CNS melanocortin circuitry, hypothalamic dopaminergic modulation, and limbic reward pathway signalling in preclinical neuroendocrine models.

Cyclic heptapeptide MC1R/MC4R agonist. Studied for melanocortin receptor pharmacology, hypothalamic energy balance, and pigmentation pathway signalling in preclinical research.

Dual GIP/GLP-1 receptor co-agonist. Studied for incretin axis synergy, adipocyte lipolysis regulation, and hypothalamic energy homeostasis in metabolic research models.

Triple GLP-1R/GIPR/GCGR receptor agonist. Studied for combined incretin, thermogenic, and glucagon-mediated energy expenditure effects in preclinical and clinical metabolic models.

GHRH(1-44)-NH2 analogue conjugated to trans-3-hexenoic acid for DPP-IV resistance. Studied for somatotropic axis activation and visceral adipose modulation in preclinical and clinical models.

Pre-mixed GHRH analogue (CJC-1295) and selective GHRP (Ipamorelin) blend. Studied for synergistic GHRHR/GHSR-1a activation and somatotropic axis modulation in preclinical models.

Ala-Glu-Asp-Gly tetrapeptide. Studied for telomerase/hTERT activation, telomere elongation in primary cell cultures, and longevity-related transcriptional regulation in preclinical models.

Mitochondria-derived 16-amino-acid peptide encoded by 12S rRNA. Studied for AMPK activation, AICAR-independent AMPK phosphorylation, metabolic homeostasis, and longevity signalling research.

Nicotinamide adenine dinucleotide — essential sirtuin co-substrate, PARP1 cofactor, and mitochondrial electron transport carrier. Studied in cellular NAD+ repletion and longevity biology research.